ROCKVILLE, Md., March 2, 2015 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific
therapies for serious infections and diseases, with a focus on
protecting the microbiome, today announced that preclinical results
supporting the development of SYN-005 for the treatment of
Pertussis will be highlighted at ECCMID 2015 (European Congress of
Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be
presented under the Respiratory Infections category all four
days at ECCMID on 50 ePoster stations, as follows:
Title: Antibody Cocktail Effectively Treats Pertussis in
a Baboon Disease Model
Authors: J. A.
Maynard1, A. Nguyen1, E.
Wagner1, J. Laber1, L. Goodfield2,
W. Smallridge2, E. T.
Harvill2, R. F.
Wolf3, J. C.
Papin3, S. Connelly4, J. A. Bristol4, M.
Kaleko4
1Universty of Texas
at Austin, Austin, TX, 2Penn State Univ.,
University Park, PA,
3Univ. of Oklahoma Health Science Center, Oklahoma City, OK, 4Synthetic
Biologics, Rockville, MD
Title: Spontaneous Identification of Bordetella
bronchiseptica in a Baboon Colony: Potential Ramifications for
Bordetella pertussis Modeling
Authors: M. Kaleko1, A. Nguyen2, E.
Wagner2, R. F.
Wolf3, J. C.
Papin3, S.Connelly1, J. A. Bristol1, J. A. Maynard2
1Synthetic Biologics, Rockville, MD, 2Universty of
Texas at Austin, Austin,
TX, 3Univ. of Oklahoma Health Science Center,
Oklahoma City, OK
"We are pleased our Pertussis candidate, SYN-005, is gaining
global acknowledgement and attention in the academic space, as we
build our preclinical portfolio to support this program," noted
Jeffrey Riley, Chief Executive
Officer of Synthetic Biologics. "We are currently pursuing
non-dilutive funding to support the clinical development of this
novel therapeutic designed to target and neutralize pertussis toxin
for the treatment of whooping cough."
Synthetic Biologics is developing SYN-005 through its Exclusive
Channel Collaboration with Intrexon Corporation (NYSE: XON) and
academic researchers at The University of
Texas at Austin to target and neutralize the pertussis toxin
in order to reduce morbidity and mortality in infected infants.
Pertussis, more commonly known as whooping cough, is a highly
contagious disease caused by the bacteria Bordetella pertussis
(B. pertussis) with symptoms that may include chronic coughing
and subsequent breathing difficulties. According to the World
Health Organization, there are approximately 50 million worldwide
cases of whooping cough each year, leading to an estimated 300,000
deaths, primarily among young, unvaccinated infants. In
September 2014, the U.S. Food and
Drug Administration (FDA) has granted Orphan Drug designation to
the Company's proprietary SYN-005 monoclonal antibody (mAb)
combination for the treatment of Pertussis.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
biotechnology company developing pathogen-specific therapies for
serious infections and diseases, with a focus on protecting the
microbiome. The Company is developing an oral biologic to protect
the gut microbiome from intravenous (IV) antibiotics for the
prevention of C. difficile infection, an oral statin
treatment to reduce the impact of methane producing organisms on
constipation-predominant irritable bowel syndrome (C-IBS), and in
collaboration with Intrexon Corporation (NYSE: XON), a monoclonal
antibody combination for the treatment of Pertussis. In addition,
the Company is developing a Phase 2 oral estriol drug for the
treatment of relapsing-remitting multiple sclerosis (MS) and
cognitive dysfunction in MS. For more information, please visit
Synthetic Biologics' website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding the potential market
size for Pertussis, and the designed treatment of SYN-005. The
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
those reflected in Synthetic Biologics' forward-looking statements
include, among others, the ability to access non-dilutive funding
to support the development of SYN-005 and the ability of SYN-005 to
perform as expected and other factors described in Synthetic
Biologics' report on Form 10-K for the year ended December 31, 2013 and any other filings with the
SEC. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no
obligation to update any forward-looking statements contained in
this release on account of new information, future events, or
otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-announces-two-poster-presentations-of-novel-monoclonal-antibody-combination-for-treatment-of-whooping-cough-pertussis-at-eccmid-2015-300043178.html
SOURCE Synthetic Biologics, Inc.